What was recalled
The U.S. Food and Drug Administration has issued a Class I recall involving specific lots of Epinephrine Injection, USP, manufactured by American Regent, Inc. This is not a minor administrative notice; it is the most serious level of recall classification, indicating that use of this product could cause serious adverse health consequences or death. The affected items are 30 mL multiple-dose vials designed for intravenous infusion, as well as intramuscular and subcutaneous use. Each vial contains a concentration of 30 mg/30 mL, which equates to 1 mg/mL of epinephrine. These are prescription-only medications, meaning they are intended for use under the direct supervision or prescription of a healthcare professional, typically in clinical settings such as hospitals, clinics, or emergency rooms.
The specific product identified in this recall is clearly labeled with the brand name American Regent and lists the manufacturer’s location as Shirley, New York, 11967. To help healthcare providers and pharmacists identify the exact items at risk, the recall targets a single National Drug Code (NDC): 0517-3030-01. It is crucial to look beyond just the NDC, however, because the recall applies only to three specific lots of this product. These are Lot 25128L1C0, which has an expiration date of August 31, 2026; Lot 25280L1C0, expiring on October 31, 2026; and Lot 26108L1C0, with a later expiration date of July 31, 2027. If you are in possession of any epinephrine injection that does not match these exact lot numbers or if the NDC differs, this specific recall action does not apply to your vial.
The distribution pattern for these recalled items was nationwide within the United States, meaning they could be found in medical facilities across all 50 states. The recall was officially initiated on August 11, 2026. While the official record provided does not specify the exact number of units involved in this recall or list specific retail stores where these might have been purchased by individual consumers, it is important to understand that because this is an Rx-only drug for intravenous and other medical uses, it is primarily distributed through hospital supply chains and professional medical distributors rather than standard retail pharmacies. Therefore, if you are a patient, you likely received this medication in a clinical setting rather than picking it up at a local pharmacy counter.
The scope of this recall is defined strictly by the manufacturer's production records. American Regent, Inc., located in Shirley, New York, identified the issue during their quality control processes. The company’s address and location are critical for any communication regarding the return or disposal of these products. Because the product is designated for multiple-dose use, the integrity of the vial and its contents is paramount. Any compromise in sterility or the introduction of foreign particles in a multi-dose environment poses a heightened risk compared to single-use items, making the precise identification of these lots essential for patient safety.
The hazard, explained
When you look at the official recall notice from the FDA regarding American Regent, Inc.’s Epinephrine Injection, USP, two distinct but equally serious safety failures stand out: the presence of particulate matter and a lack of assurance of sterility. To understand why this is dangerous, it helps to look at what is physically happening inside that 30 mL multiple-dose vial. The drug itself, epinephrine, is a potent hormone and medication used to treat severe allergic reactions (anaphylaxis), cardiac arrest, and other critical conditions where time is of the essence. In these emergencies, patients rely on the medication being perfectly pure and completely free from infection-causing agents. However, in this specific recall, the integrity of that purity has been compromised.
The first major issue is the presence of particulate matter. The FDA report identifies these particles as nylon, cellulosic material, acrylic, polyethylene, glass, and broken or leaking vial components. Physically, this means that tiny, solid fragments have ended up suspended in the liquid solution where they do not belong. These particles likely originated from the manufacturing process or the packaging materials themselves. For example, nylon and acrylic could come from filters or tubing used during production, while glass shards suggest a physical breakage in the vial or equipment. When these foreign objects are injected into the body, they can cause immediate mechanical damage. If the particles enter a blood vessel, they can travel to smaller capillaries, potentially blocking blood flow to critical tissues or organs—a condition known as embolism. This can lead to tissue death, stroke, or other severe vascular injuries depending on where the particles lodge.
The second critical failure is the lack of assurance of sterility. Sterility in injectable drugs means there are absolutely no living microorganisms, such as bacteria or fungi, present in the product. When a vial lacks this assurance, it implies that the manufacturing environment or the sealing process failed to prevent contamination. Even if the particulate matter were not present, a non-sterile epinephrine injection poses a severe risk of infection. Injecting contaminated fluid directly into the bloodstream or muscle tissue bypasses the body’s natural skin barriers. This can lead to localized abscesses at the injection site, systemic infections like sepsis, which is a life-threatening reaction to infection, or other serious inflammatory responses. The combination of foreign physical debris and potential biological contamination creates a dual threat: immediate physical trauma from the particles and delayed but potentially fatal infection from microbes.
This situation is particularly alarming because epinephrine is often used in crisis moments when patients are already vulnerable. A patient using this drug to stop a severe allergic reaction could inadvertently introduce life-threatening complications through the medication itself. The fact that the vials were described as "broken and leaking" further exacerbates the risk, as compromised packaging allows external contaminants to enter the sterile field during storage and handling, making the lack of sterility assurance even more likely. Understanding these physical mechanisms highlights why a Class I recall—the most serious category—is necessary here.
Who is most at risk
To understand who is most vulnerable in this specific recall, it is essential to first look at the nature of the product itself. Epinephrine Injection, USP, 30 mg/30 mL (1mg/mL), manufactured by American Regent, Inc., is not a standard over-the-counter medication found in a home medicine cabinet. It is a prescription-only drug classified specifically for intravenous infusion, as well as intramuscular and subcutaneous use. This means the primary group of people directly interacting with this recalled item are patients in acute care settings—such as emergency rooms, intensive care units, or operating rooms—who are receiving continuous or controlled delivery of epinephrine to manage critical conditions like severe hypotension, cardiac arrest, or anaphylaxis.
The individuals at highest risk from this particular recall are those currently receiving treatment via the affected lots. Because the product is designed for intravenous infusion, it bypasses the body’s natural barriers and enters the bloodstream directly. The hazard here involves the presence of particulate matter identified as nylon, cellulosic, acrylic, polyethylene, glass, as well as broken and leaking vials. When these particles are infused directly into a vein, they can cause immediate physical damage to blood vessels and blood cells. For patients whose immune systems are already compromised by serious illness or surgery, introducing foreign particulate matter poses a severe risk of embolism, where these particles block small blood vessels in the lungs, brain, or heart.
Elderly patients and those with pre-existing cardiovascular conditions are particularly vulnerable to the consequences of this defect. If the vials are leaking or broken, the dosage delivered may be inconsistent. In a critical situation where precise dosing is required to maintain blood pressure or heart rhythm, a lack of assurance of sterility or inaccurate delivery can lead to treatment failure. Furthermore, the presence of particulate matter increases the risk of infection and inflammatory responses. For elderly patients or those with weakened immune systems, even a minor introduction of bacteria due to sterility failures can escalate quickly into sepsis, a life-threatening systemic response to infection.
Additionally, while less common for this specific IV formulation compared to auto-injectors, patients receiving subcutaneous or intramuscular injections from these lots are also at risk. If the vials are leaking, the medication may have been exposed to environmental contaminants before use. For anyone with sensitive skin or compromised tissue integrity, such as diabetic patients or those on immunosuppressive therapy, this increases the likelihood of local infection, abscess formation, or delayed healing at the injection site.
It is also important to note that healthcare providers and pharmacy staff handling these vials are indirectly at risk. Broken vials pose a sharp injury hazard, potentially leading to needlestick injuries or exposure to contaminated materials. While they do not receive the drug themselves, their safety and ability to provide care without additional complications are impacted by the physical integrity of the packaging.
- Patients in critical care: Those relying on precise IV dosing for life-sustaining treatment.
- Elderly individuals: Who may have reduced ability to filter particulates or fight infection.
- Immunocompromised patients: Including those with cancer, HIV, or recent transplant histories.
- Cardiovascular patients: Whose blood vessels are already under stress and more susceptible to blockage from particulate matter.
How to tell if you have the recalled item
Identifying whether your specific vial of Epinephrine Injection is part of this recall requires careful attention to several distinct details printed on the packaging and the container itself. Because this product is a prescription-only medication intended for serious medical use, it is crucial not to rely on general assumptions about the bottle’s appearance or even just the brand name alone. While the manufacturer is American Regent, Inc., located in Shirley, New York, that information alone does not confirm if your specific unit is affected. You must verify four critical pieces of data: the National Drug Code (NDC), the Lot number, and the Expiration date. If any one of these matches the recall details, you should treat the item as recalled immediately.
First, locate the NDC on the outer carton or the label of the vial. The recalled product specifically carries the code 0517-3030-01. This number is your primary filter. If your NDC does not match this exact sequence, the item is not part of this specific recall action, regardless of other similarities. Next, examine the Lot number printed on the label. The FDA’s notice identifies three specific lots that are subject to this Class I recall:
- 25128L1C0
- 25280L1C0
- 26108L1C0
If your vial’s lot number matches any of these three codes, it is implicated in the recall. Finally, cross-reference the expiration date associated with each lot to ensure accuracy. The lot 25128L1C0 is scheduled to expire on August 31, 2026. The lot 25280L1C0 expires on October 31, 2026. The final affected lot, 26108L1C0, has an expiration date of July 31, 2027. It is important to note that the product description specifies this is a 30 mL multiple-dose vial containing Epinephrine Injection, USP, at a concentration of 30 mg/30 mL (which equals 1mg/mL). This formulation is designated for intravenous infusion, intramuscular, and subcutaneous use.
Where did you acquire this item? The recall distribution pattern indicates that these products were distributed nationwide within the United States. Therefore, the store or pharmacy where you purchased it does not help determine if it is recalled; only the printed codes do. If you have a healthcare provider or institution inventory, check their records against these lot numbers. If you are a patient at home, look closely at the label on the vial and the box it came in. Do not guess. The presence of particulate matter—such as nylon, glass, or acrylic fragments—and the lack of sterility assurance are invisible hazards that cannot be detected by looking at the liquid’s clarity alone. Visual inspection for broken vials is noted in the hazard description, but the primary method of identification remains the printed Lot and NDC numbers. If you cannot find these numbers, or if they do not match the specific codes listed above, your item is likely safe from this specific recall. However, if you are unsure, contact your pharmacist or healthcare provider with the physical vial in hand for confirmation.
What to do — step by step
If you have been prescribed or are currently using Epinephrine Injection, USP from American Regent, Inc., the most important immediate action is to stop using these specific products right away. Because the recall classification is Class I, which indicates a situation where use of the product could cause serious adverse health consequences or death, ignoring this warning is not an option. However, stopping use does not mean you should panic or attempt to manage a medical emergency without guidance. Epinephrine is a critical medication often used for severe allergic reactions (anaphylaxis) and other urgent conditions. Therefore, your first practical step is to contact your healthcare provider or pharmacist immediately. Explain that you have this specific recalled product and ask them to help you secure a replacement from a different manufacturer or lot number that has not been affected by this recall. They can also advise you on whether you need a temporary bridge supply while the issue is resolved, ensuring your care is not interrupted during the transition.
Once you have secured alternative medical supplies, you must handle the recalled vials with extreme care. The FDA report highlights that these 30 mL multiple-dose vials may contain particulate matter such as nylon, glass, or acrylic fragments, and some vials are broken or leaking. Do not attempt to inspect the contents yourself by opening them if they appear intact, as this could expose you to contaminants or increase the risk of injury from broken glass. Instead, leave the vials in their original packaging if possible, or place them in a secure, puncture-resistant container to prevent accidental needle sticks or exposure to any leaking solution. Clearly label these containers as “RECALLED PRODUCT – DO NOT USE” to ensure that anyone else in your household, caregiver, or medical facility knows these items are hazardous and must not be administered to patients.
The next step involves the proper disposal of the recalled items. Since the remedy for this specific recall is not explicitly stated as a return-to-manufacturer process for patients, you should not mail these vials back to American Regent unless instructed otherwise by your healthcare provider or local health authorities. Instead, follow your local community’s guidelines for disposing of hazardous pharmaceutical waste. Many pharmacies and hospitals have designated take-back programs for unsafe or recalled medications. If no such program is available, consult your local waste management authority for instructions on safe disposal that prevents environmental contamination and accidental ingestion by others. Keep a record of the lot numbers (25128L1C0, 25280L1C0, or 26108L1C0) and the expiration dates associated with your vials, as you may need to provide this information to your healthcare provider for medical records or insurance purposes.
Finally, stay vigilant for any symptoms that might suggest exposure to the recalled product. If you have already used one of these vials and experience unusual reactions, such as signs of infection (fever, redness at the injection site) or unexpected physical symptoms that could be linked to particulate matter entering your bloodstream, seek medical attention promptly. Report any adverse events to the FDA MedWatch program. This helps authorities track the real-world impact of the recall and ensures that other patients are protected. Remember, while this situation is serious, acting calmly and following these steps will help keep you and your loved ones safe.
Your refund, repair, or replacement options
When you encounter a Class I drug recall, the immediate question is often, "What happens to my money and my health?" It is important to approach this situation with clarity and calm. First, let’s address the most critical safety reality: there are no repair options for pharmaceutical products. You cannot fix a vial that contains particulate matter or lacks sterility assurance. Attempting to filter, clean, or repurpose these items is not only ineffective but dangerously misleading. The remedy in this scenario is strictly one of removal and return. The goal is to get the unsafe product out of your possession and back to the manufacturer or distributor so it can be destroyed safely, ensuring it never reaches a patient who needs it. According to the official recall facts released by the FDA on August 11, 2026, the specific remedy terms—such as direct refund amounts, prepaid shipping labels, or specific replacement protocols—are not explicitly stated in the public summary. This is common in initial Class I drug recalls, where the primary regulatory directive is immediate cessation of use and return to the distributor rather than a consumer-facing retail refund process. Because Epinephrine Injection is a prescription-only (Rx) medication for intravenous, intramuscular, or subcutaneous use, your path to resolution will differ significantly from returning a defective toaster or a shirt. You are not dealing with a standard retail store; you are dealing with a medical supply chain. Your primary action step is to contact the healthcare provider who prescribed this specific medication or the pharmacy that dispensed it. Do not attempt to contact American Regent, Inc., directly for a refund unless explicitly instructed by your pharmacist or doctor, as they likely do not handle consumer-level financial transactions for hospital-grade or prescription IV infusions. The pharmacy or medical facility will have received a recall notice from their supplier. They are responsible for initiating the return process with the wholesaler who supplied them. This is where your "refund" or credit happens. If you paid out-of-pocket, the pharmacy will typically reverse the charge to your insurance provider or issue a store credit/refund once they confirm the return of the lots. To facilitate this process, you must be prepared to provide specific details. Have your prescription bottle or vial label ready. You need to identify the National Drug Code (NDC), which is 0517-3030-01 for the recalled product. More importantly, you must know the lot number. The recall affects three specific lots: 25128L1C0 (expired August 31, 2026), 25280L1C0 (expired October 31, 2026), and 26108L1C0 (expired July 31, 2027). If your vial’s lot number matches one of these three, it is part of the recall. If it does not, you are safe to use it, though verifying with your provider is always wise. In terms of replacement, you do not need to "buy" a new vial online or at a store. Your healthcare provider will issue a new prescription for a different lot number from a different manufacturing batch that has passed sterility and particulate checks. The financial burden of the defective product falls on the manufacturer and the supply chain, not on you. You should focus entirely on discontinuing use immediately if you have the affected lots and contacting your prescriber to discuss alternative treatments or safe replacements. Do not wait for a letter in the mail; proactive communication with your medical team ensures you receive appropriate care without delay.What can happen if you ignore it
When you come across a Class I drug recall, it is easy to feel overwhelmed by the terminology and wonder if the risk is truly as immediate as the FDA suggests. However, understanding what happens when you continue to use a product like this recalled Epinephrine Injection is crucial for your safety. This specific recall involves multiple-dose vials that have been identified with particulate matter—visible particles such as nylon, cellulosic fibers, acrylic fragments, polyethylene bits, and glass shards—as well as a lack of assurance of sterility. Ignoring these defects is not merely a breach of protocol; it introduces serious, potentially life-threatening complications into your medical treatment.
The most immediate danger lies in the particulate matter itself. Epinephrine is often administered intravenously for emergency situations where seconds count. If you use a vial containing glass or hard plastic fragments, those particles travel directly into your bloodstream. Instead of being filtered out harmlessly, these sharp objects can cause micro-trauma to blood vessel walls and capillaries. More critically, they pose a significant risk of embolism. A particle can block small blood vessels in the lungs, brain, or other vital organs, leading to tissue damage or death. Even smaller, less visible particles can trigger severe inflammatory reactions within the body, causing your immune system to attack the foreign material, which can lead to fever, chills, and systemic inflammation that complicates any existing medical condition.
Equally dangerous is the issue of sterility. The recall notes a "lack of assurance of sterility," which means the vials may harbor bacteria or fungi. When you inject a non-sterile solution directly into your vein or muscle, you are bypassing the body’s natural skin barriers. This can lead to serious infections such as sepsis, a life-threatening response to infection that causes widespread inflammation throughout the body. Sepsis can lead to tissue damage, organ failure, and death if not treated aggressively and immediately. Because this is a multiple-dose vial, the risk increases with every time the stopper is pierced, potentially introducing contaminants into the remaining solution.
Furthermore, using compromised Epinephrine during an emergency can have catastrophic consequences due to dosage uncertainty. Broken or leaking vials may not deliver the full prescribed amount of medication. In a cardiac arrest or severe allergic reaction (anaphylaxis), even a small deficit in dosage can mean the difference between recovery and fatality. If the drug is contaminated, it might also react chemically with the epinephrine, rendering it ineffective when you need it most. Therefore, ignoring this recall does not just expose you to minor inconvenience; it exposes you to the risk of embolism, severe infection, and treatment failure during critical moments.
- Vascular Damage: Particles can block blood vessels, leading to stroke, pulmonary embolism, or organ damage.
- Infection Risk: Non-sterile products can introduce bacteria into the bloodstream, causing sepsis or localized abscesses.
- Treatment Failure: Leaking or broken vials may deliver incorrect dosages, failing to treat the emergency condition effectively.
Staying safe: broader tips
While this specific recall highlights the critical importance of verifying the integrity of sterile pharmaceutical products, maintaining safety with injectable medications and medical supplies extends far beyond a single manufacturer’s error. Epinephrine is often stored in homes for emergency use, particularly for individuals with severe allergies or those who carry auto-injectors like EpiPens. To ensure these life-saving tools are ready when you need them most, it is essential to adopt a routine of proactive inventory management. Check the expiration dates on all your medical supplies at least twice a year, ideally when you change your clocks for daylight saving time. An expired or compromised medication may not only be ineffective but could also degrade into harmful byproducts, posing risks similar to the particulate matter issues seen in this recall.
Proper storage is equally vital. Most injectable epinephrine and other sensitive medications require protection from extreme temperatures and direct sunlight, which can break down the chemical structure of the drug before its expiration date even arrives. Keep your supplies in a cool, dry place away from windows or heaters. If you use multiple-dose vials or reusable syringes, strict hygiene is non-negotiable. Always wash your hands thoroughly before handling any injection equipment, and never share needles or pens with others to prevent cross-contamination. Consider keeping a dedicated, clean kit for emergency access that includes not just the medication, but also alcohol swabs and sharps containers for safe disposal.
Beyond storage and hygiene, staying informed is your best defense against unexpected product failures. Sign up for safety alerts directly from the U.S. Food and Drug Administration (FDA) via their website or mobile app. These notifications often appear before a problem becomes widespread, giving you time to act. Additionally, regularly visit the FDA’s official recall database to check if any products in your home have been flagged. Do not rely solely on store notifications or manufacturer emails, which can sometimes be delayed or missed.
Finally, educate yourself and your family on what to look for when inspecting medical supplies. Be vigilant for any changes in the appearance of liquid medications, such as cloudiness, discoloration, or visible particles that were not present before. If a vial looks damaged, cracked, or if the seal appears broken, do not use it under any circumstances. Dispose of it safely according to local pharmaceutical waste guidelines and replace it immediately. By treating your medical supplies with the same diligence you would apply to other critical home safety devices, like smoke detectors, you significantly reduce the risk of adverse health events caused by product defects or misuse.